Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BAZ2B | Q9UIF8 | 3/20 | 0.46 |
| ▸ | MCHR1 | Q99705 | 8/20 | 0.42 |
| ▸ | HTR5A | P47898 | 2/20 | 0.39 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.38 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3477090 | 0.93 | BAZ2B (0.53) | BAZ2BMCHR1HTR5AHDAC10HDAC6 | |
| SCHEMBL1006124 | 0.90 | BAZ2B (0.40) | BAZ2BMCHR1HTR5AEGLN1 | |
| SCHEMBL3475264 | 0.85 | BAZ2B (0.44) | BAZ2BMCHR1HTR5AHDAC6EGLN1 | |
| SCHEMBL1007584 | 0.84 | KRAS (0.46) | BAZ2BMCHR1HDAC10HDAC6HDAC1 | |
| SCHEMBL1004240 | 0.84 | GRM5 (0.46) | BAZ2BMCHR1HTR5AHDAC10HDAC6 | |
| SCHEMBL1005802 | 0.79 | HTR6 (0.46) | BAZ2B | |
| SCHEMBL989561 | 0.78 | MCHR1 (0.38) | BAZ2BMCHR1HTR5AHDAC10HDAC6 | |
| SCHEMBL12127719 | 0.78 | HDAC6 (0.52) | BAZ2BMCHR1HDAC10HDAC6HDAC8 | |
| SCHEMBL3476875 | 0.77 | BAZ2B (0.50) | BAZ2BHTR5AHDAC10HDAC6HDAC1 | |
| SCHEMBL9966179 | 0.77 | ALOX5 (0.53) | HTR5AKCNH2CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8637501-B2 | Azinone-substituted azepino[b]indole and pyrido-pyrrolo-azepine MCH-1 antagonists, methods of making, and use thereof | ALBANY MOLECULAR RESEARCH, INC. (US) | 2014-01-28 | — | — | US | disclosed |
| EP-2448585-B1 | AZINONE-SUBSTITUTED AZEPINO[B]INDOLE AND PYRIDO-PYRROLO-AZEPINE MCH-1 ANTAGONISTS, METHODS OF MAKING, AND USE THEREOF | ALBANY MOLECULAR RES INC (US) | 2014-01-01 | — | — | EP | disclosed |
| EP-2448585-A1 | AZINONE-SUBSTITUTED AZEPINO[B]INDOLE AND PYRIDO-PYRROLO-AZEPINE MCH-1 ANTAGONISTS, METHODS OF MAKING, AND USE THEREOF | Albany Molecular Research, Inc. (US) | 2012-05-09 | — | — | EP | disclosed |
| US-20110003793-A1 | AZINONE-SUBSTITUTED AZEPINO[b]INDOLE AND PYRIDO-PYRROLO-AZEPINE MCH-1 ANTAGONISTS, METHODS OF MAKING, AND USE THEREOF | ALBANY MOLECULAR RESEARCH, INC. (US) | 2011-01-06 | — | — | US | disclosed |
| WO-2011003005-A1 | AZINONE-SUBSTITUTED AZEPINO[B]INDOLE AND PYRIDO-PYRROLO-AZEPINE MCH-1 ANTAGONISTS, METHODS OF MAKING, AND USE THEREOF | ALBANY MOLECULAR RESEARCH, INC. (US) | 2011-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003793-A1 | AZINONE-SUBSTITUTED AZEPINO[b]INDOLE AND PYRIDO-PYRROLO-AZEPINE MCH-1 ANTAGONISTS, METHODS OF MAKING, AND USE THEREOF | MCHR1, MCHR2, HTR1E | BAZ2B 1341/4885MCHR1 1/4885HTR5A 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.